OIE Standard on principles and methods of validation of diagnostic assays for infectious diseases

OIE Regional Workshop for OIE National Focal Points for Veterinary Products
Ottawa, Canada
25 – 27 August 2014

Dr François Diaz
OIE Scientific and Technical Department

OIE standards

*Terrestrial Animal Health Code* – mammals, birds and bees

*Aquatic Animal Health Code* – fish, molluscs and crustaceans

*Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*

*Manual of Diagnostic Tests for Aquatic Animals*

Codes and Manuals available on the OIE website
Chapters 1.1.5. of the OIE Terrestrial Manual and 1.1.2. of the Aquatic Manual

- Two chapters similar on diagnostic test validation covering all the types of tests in terrestrial and aquatic animals
- Title: *Principles and methods of validation of diagnostic assays for infectious diseases*
- Provides principles and methods for diagnostic test validation
- Included for the first time in the *Terrestrial Manual* in 2000 and in the *Aquatic Manual* in 2003

Chapters 1.1.5. of the OIE Terrestrial Manual and 1.1.2. of the Aquatic Manual

- Current version updated by an OIE *ad hoc* Group on validation of Diagnostic tests and adopted by the World Assembly of Delegates in 2013
- Available and downloadable on the OIE website at: 
  http://www.oie.int/en/international-standard-setting/aquatic-manual/access-online/
  http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/
Chapters 1.1.5. of the OIE Terrestrial Manual and 1.1.2. of the Aquatic Manual

Seven (7) Guidelines have been developed in complement of this standard:

- Development and optimisation of antibody detection assays
- Development and optimisation of antigen detection tests
- Development and optimisation of nucleic acid detection tests
- Measurement of Uncertainty

Chapters 1.1.5. of the OIE Terrestrial Manual and 1.1.2. of the Aquatic Manual

Seven (7) Guidelines have been developed in complement of this standard (contd):

- Statistical approaches to validation (including Latent Class Models)
- Selection and use of reference samples and panels
- Principles & methods for the validation of diagnostic tests for infectious diseases applicable to wildlife
- *Comparability of assays after minor changes in a validated test method (under study)*
I. Assay development pathway

Definition of the intended purpose(s),
Design of the test method,
Selection of the reference materials,
Calibration, optimisation and standardisation,
Robustness,
Etc.

The most common purposes are to:

- Contribute to the demonstration of freedom from infection in a defined population (country/zone/compartment/herd)
- Certify freedom from infection or presence of the agent in individual animals or products for trade/movement
- Contribute to the eradication of diseases or elimination of infection from defined populations
- Confirm diagnosis of suspect or clinical cases
- Estimate prevalence of infection or exposure to facilitate risk analysis
- Determine immune status of individual animals or populations (post-vaccination)
I. Assay development pathway

Calibration of the assay to standards reagents:

- International and national reference standards
  OIE standards or other international reference standards. If no available, national reference standards becomes the standard of comparison

- In-house standard
  Should be calibrated against an international or national standard

- Working standard
  Calibrated against international, national or in-house standard and prepared in large quantities for routine use in each diagnostic run of the assay

List of OIE approved international standard sera available on the OIE website:

II. Assay validation pathway

Definition of the validation:

The validation of a diagnostic test is a **process** that determines the **fitness of this test**, which has been properly developed, optimised and standardised, for an **intended purpose and for specific specimen(s) and specie(s)**.

It is an ongoing process.
II. Assay validation pathway

The OIE has defined a chronological validation pathway with 4 stages or steps:

• Stage 1: Analytical performance characteristics
• Stage 2: Diagnostic performance of the assay
• Stage 3: Reproducibility
• Stage 4: Programme implementation

Stage 1: Analytical performance characteristics

• **Analytical sensitivity**: smallest detectable amount of analyte that can be measured with a defined certainty

• **Analytical specificity**: Degree to which the assay distinguishes between the target analyte and other components in the sample matrix

• **Repeatability**: Level of agreement between replicates of a sample both within and between runs of the same test method in a given laboratory
II. Assay validation pathway

➢ Stage 2: Diagnostic performance of the assay
  • Selection of reference animals
  • Diagnostic specificity: Proportion of known uninfected reference animals that test negative in the assay
  • Diagnostic sensitivity: Proportion of known infected reference animals that test positive in the assay
  • Comparison with existing diagnostic test – Final Threshold determination

II. Assay validation pathway

➢ Stage 3: Reproducibility
  • Definition: ability of a test method to provide consistent results when applied to aliquots of the same samples tested at different laboratories
  • Provides additional data for the estimation of the repeatability
  • Provides data on the ruggedness if the test method has been developed as a diagnostic kit.
II. Assay validation pathway

- **Stage 4: Programme implementation**
  - Extensive application of the test method in different laboratories,
  - Interpretation of tests results, and
  - International recognition

II. Assay validation pathway

- **When a diagnostic test method is considered as validated?**
  - Different replies depending of the test methods, of the samples available and the status of the validation
II. Assay validation pathway

➢ When a diagnostic test method is considered as validated?

Assay Validation Pathway

- STAGE 1
  • Adjunct tests or procedures:
    Tests or procedures that are applied to an analyte that has been detected in a primary assay with the purpose to further characterise this analyte.
    Do not require the validation of the diagnostic perf.
    Example: VNT to type an isolated virus or molecular sequencing to confirm a real time PCR result.
II. Assay validation pathway

➢ When a diagnostic test method is considered as validated?

STAGE 2

• Provisional recognition:
  Situation where samples from the target population are scarce and animals difficult to access (e.g. wildlife)

  Prov. recogn. consists in stage 1 completed + preliminary estimates of DSp and DSe + preliminary estimates of reproducibility

STAGE 3

• Validated for the original intended purpose(s):
  A diagnostic test method that has completed the first three stages of the validation pathway can be designated as “validated for the original intended purpose(s)”. 
III. Validation status retention

- Check and maintain the performance characteristics,
- Organisation of regular proficiency testing,
- Modifications (e.g. for new subtypes of existing pathogens) and enhancements (e.g. to improve assay efficiency or cost-effectiveness),
- Consideration for other purposes or other species,
- Etc.
Verification of existing assays (in-house validation)

1. A limited verification of both ASp and ASe using available reference materials, whether they be external and/or locally acquired from the target population.

2. A limited Stage 2 validation should be considered in the context of the intended application and target population before the assay is put into routine diagnostic use.

Support - OIE Collaborating Centres

- ELISA and Molecular Techniques in Animal Disease Diagnosis
  FAO/IAEA Animal Production and Health Laboratory
  Agriculture and Biotechnology Laboratory
  IAEA Laboratories
  Wagramerstrasse 5
  P.O. Box 100
  1400 Vienna
  AUSTRIA
  Tel: +43-1 2600.28.355
  Fax: +43 1 2600.280221
  Email: adama.diallo@iaea.org
Support - OIE Collaborating Centres

- Biotechnology-based Diagnosis of Infectious Diseases in Veterinary Medicine
  National Veterinary Institute, Travvägen 22, 75189 Uppsala
  SWEDEN
  Tel: +46-18 67.40.00 - Fax: +46-18 67.44.67
  Email: sandor.belak@sva.se

Swedish University of Agricultural Sciences
Department of Biomedical Sciences and Veterinary Public Health
P.O. Box 7036, 75007 Uppsala
SWEDEN
Tel: +46-18 67.41.35 - Fax: +46-18 30.91.62
Email: sandor.belak@slu.se

Thank you for your attention